Department of Clinical & Translational Science, The Peekie Nash Carpenter Endowed Chair in Medicine, Creighton University School of Medicine, CRISS II Room 510, 2500 California Plaza, Omaha, NE, 68178, USA.
Department of Cardiothoracic Surgery, University of Nebraska Medical Center, Omaha, NE, USA.
J Cardiovasc Transl Res. 2018 Aug;11(4):292-307. doi: 10.1007/s12265-018-9813-1. Epub 2018 May 24.
Ischemic preconditioning is a process which serves to mitigate reperfusion injury. Preconditioning of the heart can be achieved through natural, pharmacological, and mechanical means. Mechanical preconditioning appears to have the greatest chance of good outcomes while methods employing pharmacologic preconditioning have been largely unsuccessful. Remote ischemic preconditioning achieves a cardioprotective effect by applying cycles of ischemia and reperfusion in a distal limb, stimulating the release of a neurohumoral cardioprotective factor incited by stimulation of afferent neurons. The cardioprotective factor stimulates the reperfusion injury salvage kinase (RISK) and survivor activator factor enhancement (SAFE) signaling cascades in cardiomyocytes which promote cell survival by the expression of anti-apoptotic genes and inhibition of the opening of mitochondrial permeability transition pores. Clinical application of ischemic preconditioning involving targets in the RISK and SAFE signaling appears promising in the treatment of acute myocardial infarction; however, clinical trials have yet to demonstrate additional benefit to current therapy.
缺血预处理是一种减轻再灌注损伤的过程。心脏的预处理可以通过自然、药理学和机械手段来实现。机械预处理似乎有最大的机会获得良好的结果,而使用药理学预处理的方法在很大程度上是不成功的。远程缺血预处理通过在远端肢体施加缺血和再灌注循环来实现心脏保护作用,刺激传入神经元刺激释放神经激素心脏保护因子。该心脏保护因子刺激再灌注损伤挽救激酶 (RISK) 和存活激活因子增强 (SAFE) 信号级联反应,通过表达抗凋亡基因和抑制线粒体通透性转换孔的开放来促进细胞存活。涉及 RISK 和 SAFE 信号通路靶点的缺血预处理的临床应用在急性心肌梗死的治疗中似乎很有前景;然而,临床试验尚未证明对现有治疗有额外的益处。